Popular weight loss drugs have been linked to gastrointestinal, mental health, and vision problems, but the benefits appear ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

As optimism for GLP-1 receptor agonists for weight loss has grown, so too has their use in children. Currently, liraglutide ...

Glucagon-like peptide-1 receptor (GLP-1) agonists, particularly semaglutide, could be effective in reducing alcohol-related hospitalisations. Read more!

Coya Therapeutics (COYA) releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan….”Given my recent ...

In recent years, GLP-1 agonist medications like Ozempic have gained notoriety for their weight loss effects and blood sugar regulation. However, these pharmaceuticals come with a host of potential ...

A long-term study suggests GLP-1 agonists, especially semaglutide, may lower the risk of alcohol use disorder hospitalizations, highlighting the potential for novel treatments pending further ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

In part 1 of the so-called ESSENCE trial, treatment with the GLP-1 receptor agonist resulted in higher week-72 rates of steatohepatitis resolution without worsening of liver fibrosis (63% vs 34% ...

Dr, Garner said, "Glucagon-like peptide-1 (GLP-1) receptor agonists represent a significant advancement in the treatment of ...